代谢相关脂肪性肝病治疗进展  

Progress on the treatment of metabolic associated fatty liver disease

作　　者：杨彬[1] 张瑞 Yang Bin;Zhang Rui(Department of Gastroenterology,Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Shanxi Taiyuan 030032,China;Department of Gastroenterology,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Shanxi Taiyuan 030032,China)

机构地区：[1]山西医科大学第三医院(山西白求恩医院山西医学科学院同济山西医院)消化内科,山西太原030032 [2]山西白求恩医院(山西医学科学院同济山西医院)消化内科,山西太原030032

出　　处：《中国肝脏病杂志(电子版)》2024年第4期25-30,共6页Chinese Journal of Liver Diseases:Electronic Version

基　　金：山西省科技攻关项目(20140313013-7)。

摘　　要：代谢相关脂肪性肝病(metabolic associated fatty liver disease,MAFLD)是一种受多种机制(包括代谢、遗传、环境和肠道微生物因素)调节的复杂疾病。随时间推移,其发病率呈上升趋势。近年来,研究人员积极开展有关MAFLD的研究,新的靶点和药物不断被发现。然而目前尚无美国食品药品监督管理局批准的特效药物治疗MAFLD,现有的标准治疗依赖改善生活方式,主要包括饮食和运动。本文对MAFLD的发病机制和治疗进展进行综述,以期为临床医生提供关于MAFLD治疗的新方向。Metabolic associated fatty liver disease(MAFLD)is a complex disease regulated by multiple mechanisms,including metabolic,genetic,environmental and gut microbiological factors.The incidence has shown an increasing trend.In recent years,many studies on MAFLD have been actively carried out,remarkable results have been achieved,and new targets and drugs have been discovered.However,there are currently no American Food and Drug Administration-approved specific drugs for the treatment of MAFLD,and the existing standard treatment relies on improving lifestyle,mainly including diet and exercise.The purpose of this review is to provide an overview of the pathogenesis and progress in the treatment of MAFLD and to provide clinicians with new directions on the treatment of MAFLD.

关 键 词：代谢相关脂肪性肝病 代谢相关脂肪性肝炎 生活方式 药物治疗 减肥手术 

分 类 号：R57[医药卫生—消化系统]